

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO			Complete If Known		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)			Application Number	10/594,097	
			Filing Date	September 25, 2006	
			First Named Inventor	Ulrich Hersel	
			Art Unit	N/A	
			Examiner Name	Not Yet Assigned	
Sheet	1	of	2	Attorney Docket Number	13907-00007-US

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	AA*	US-6,720,306-A1	04-13-2004	Greenwald et al.	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document Country Code ³ -Number- Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁴
	BA	WO-99/30727	06-24-1999	Enzon Inc et al.		See US-6720306
	BB	WO-02/089789	11-14-2002	Enzon Inc		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. * CITE NO.: Those application(s) which are marked with an single asterisk (*) next to the Cite No. are not supplied (under 37 CFR 1.98(a)(2)(iii)) because that application was filed after June 30, 2003 or is available in the IFW. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS						
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.				T ²
	CA	NA et al., "Monitoring of peptide acylation inside degrading PLGA microspheres by capillary electrophoresis and MALDI-TOF mass spectrometry," <i>Journal of Controlled Release</i> , (2003), pp. 291-299, Vol. 92.				
	CB	DUNCAN, "The Dawning Era of Polymer Therapeutics," <i>Nature Reviews</i> , (May 2003), pp. 347-360, Vol. 2.				
	CC	MATSUMURA et al., "A New Concept for Macromolecular Therapeutics in Cancer Chemotherapy: Mechanism of Tumor-tropic Accumulation of Proteins and the Antitumor Agent Smancs," <i>Cancer Research</i> , (December 1986), pp. 6387-6392, Vol. 46.				
	CD	CALICETI et al., "Pharmacokinetic and biodistribution properties of poly(ethylene glycol)-protein conjugates," <i>Advanced Drug Delivery Reviews</i> , (2003), pp. 1261-1277, Vol. 55.				
	CE	PELEG-SCHULMAN et al., "Reversible PEGylation: A Novel Technology to Release Native Interferon $\alpha 2$ over a Prolonged Time Period," <i>J. Med. Chem.</i> , (2004), pp. 4897-4904, Vol. 47.				
	CF	TESTA et al., "Metabolic Hydrolysis and Prodrug Design," <i>Hydrolysis in Drug and Prodrug Metabolism</i> , (2003), pp. 4-5.				
	CG	LUO et al., "A Hyaluronic Acid-Taxol Antitumor Bioconjugate Targeted to Cancer Cells," <i>Biomacromolecules</i> , (2000), pp. 208-218, Vol. 1.				
	CH	CHENG et al., "Synthesis of Linear, β -Cyclodextrin-Based Polymers and Their Camptothecin Conjugates," <i>Bioconjugate Chem.</i> , (2003), pp. 1007-1017, Vol. 14.				
	CI	BHATT et al., "Synthesis and in Vivo Antitumor Activity of Poly(L-glutamic acid) Conjugates of 20(S)-Camptothecin," <i>J. Med. Chem.</i> , (2003), pp. 190-193, Vol. 46.				
	CJ	GREENWALD et al., "Drug Delivery Systems Employing 1,4- or 1,6-Elimination: Poly(ethylene glycol) Prodrugs of Amine-Containing Compounds," <i>J. Med. Chem.</i> , (1999), pp. 3657-3667, Vol. 42.				
	CK	TESTA et al., "The Hydrolysis of Carboxylic Acid Ester Prodrugs," <i>Hydrolysis in Drug and Prodrug Metabolism</i> , (2003), pp. 420-534, Chapter 8.				

Examiner Signature	/Nissa Westerberg/	Date Considered	05/23/2011
--------------------	--------------------	-----------------	------------

517730

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /N.M.W./

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete If Known	
				Application Number	10/594,097
				Filing Date	September 25, 2006
				First Named Inventor	Ulrich Hersel
				Art Unit	N/A
				Examiner Name	Not Yet Assigned
Sheet	2	of	2	Attorney Docket Number	13907-00007-US

CL	CAVALLARO <i>et al.</i> , "Polymeric Prodrug for Release of an Antitumoral Agent by Specific Enzymes," <i>Bioconjugate Chem.</i> , (2001), pp. 143-151, Vol. 12.
CM	SATCHI-FAINARO <i>et al.</i> , "PDEPT: Polymer-Directed Enzyme Prodrug Therapy. 2. HPMA Copolymer- β -lactamase and HPMA Copolymer-C-Dox as a Model Combination", <i>Bioconjugate Chem.</i> , (2003), pp. 797-804, Vol. 14.
CN	DUNCAN <i>et al.</i> , "Polymer-drug conjugates, PDEPT and PELT; basic principles for design and transfer from the laboratory to clinic," <i>Journal of Controlled Release</i> , (2001), pp. 135-146, Vol. 74.
CO	WIWATTANAPATAPEE <i>et al.</i> , "Dendrimers conjugates for colonic delivery of 5-aminosalicylic acid," <i>Journal of Controlled Release</i> , (2003), pp. 1-9, Vol. 88.
CP	GARMAN <i>et al.</i> , "The preparation and properties of novel reversible polymer-protein conjugates," <i>FEBS Letters</i> , (November 1987), pp. 361-365, Vol. 223, No. 2.
CQ	LEE <i>et al.</i> , "Drug Delivery Systems Employing 1,6-Elimination: Releasable Poly(ethylene glycol) Conjugates of Proteins," <i>Bioconjugate Chem.</i> , (2001), pp. 163-169, Vol. 12.
CR	GREENWALD <i>et al.</i> , "Drug Delivery Systems Based on Trimethyl Lock Lactonization: Poly(ethylene glycol) Prodrugs of Amino-Containing Compounds," <i>J. Med. Chem.</i> , (2000), pp. 475-487, Vol. 43.
CS	GREENWALD <i>et al.</i> , "A New Aliphatic Amino Prodrug System for the Delivery of Small Molecules and Proteins Utilizing Novel PEG Derivatives," <i>J. Med. Chem.</i> , (2004), pp. 726-734, Vol. 47.
CT	SHABAT <i>et al.</i> , "Chemical Adaptor Systems," <i>Chem. Eur. J.</i> , (2004), pp. 2626-2634, Vol. 10.
CU	LEE <i>et al.</i> , "Targeted Enzyme-Responsive Drug Carriers: Studies on the Delivery of a Combination of Drugs," <i>Angew. Chem.</i> , (2004), pp. 1707-1710, Vol. 116.
CV	PEPPAS <i>et al.</i> , "Hydrogels in pharmaceutical formulations," <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , (2000), pp. 27-46, Vol. 50.
CW	HENNINK <i>et al.</i> , "Novel crosslinking methods to design hydrogels," <i>Advanced Drug Delivery Reviews</i> , (2002), pp. 13-36, Vol. 54.
CX	ESFAND <i>et al.</i> , "Poly(amidoamine) (PAMAM) dendrimers: from biomimicry to drug delivery and biomedical applications," <i>DDT</i> , (April 2001), pp. 427-436, Vol. 6, No. 8.
CY	BOAS <i>et al.</i> , "Dendrimers in drug research," <i>Chem. Soc. Rev.</i> , (2004), pp. 43-63, Vol. 33.
CZ	GRAYSON <i>et al.</i> , "Convergent Dendrons and Dendrimers: from Synthesis to Applications," <i>Chem. Rev.</i> , (2001), pp. 3819-3867, Vol. 101.
CA1	GREENE <i>et al.</i> , "Protective Groups in Organic Synthesis," <i>John Wiley & Sons</i> , (1999), Third Edition.
CB1	AMIR <i>et al.</i> , "Self-Immolative Dendrimers," <i>Angew. Chem. Int. Ed.</i> , (2003), pp. 4494-4499, Vol. 42.
CC1	SAUERBREI <i>et al.</i> , "An Enzyme-Labile Linker Group for Organic Syntheses on Solid Supports," <i>Angew. Chem. Int. Ed.</i> , (1998), pp. 1143-1146, Vol. 37, No. 8.
CD1	DE GROOT <i>et al.</i> , "Elongated Multiple Electronic Cascade and Cyclization Spacer Systems in Activatable Anticancer Prodrugs for Enhanced Drug Release," <i>J. Org. Chem.</i> , (2001), pp. 8815-8830, Vol. 66.
CE1	ANTCZAK <i>et al.</i> , "A New Acivicin Prodrug Designed for Tumor-Targeted Delivery," <i>Bioorganic & Medicinal Chemistry</i> , (2001), pp. 2843-2848, Vol. 9.

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

*Applicant's unique citation designation number (optional). *Applicant is to place a check mark here if English language Translation is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /N.M.W./

Examiner Signature	/Nissa Westerberg/	Date Considered	05/23/2011
--------------------	--------------------	-----------------	------------